Medtronic Maps Out MiniMed Swap Schedule While Cardiac Unit Secures Four Regulatory Green Lights

Medtronic's MiniMed exchange offer pricing runs Oct 5-7, while its heart unit lands FDA and CE clearances and new CPT codes.

Medtronic is entering a pivotal stretch that pits structural housekeeping against a steady drumbeat of clinical and regulatory wins. With the separation of its diabetes arm MiniMed now roughly three weeks old, the medical technology group is simultaneously tying up loose ends on the spinoff and pushing new heart devices through approval channels on both sides of the Atlantic.

The stock has drifted 2.2% lower since the MiniMed split was set in motion. On Friday, shares closed at EUR 76.72, down 0.3% on the day, extending a 30-day decline to 3.6%.

Exchange Offer Enters Its Pricing Phase

Nasdaq has laid out the timetable for the next formal step in the portfolio overhaul. A three-day pricing period for the MiniMed share exchange offer kicks off on October 5 and runs through October 7. Unless it is extended or wrapped up early, the offer itself closes at midnight New York time on October 9.

Medtronic's proposal covers as many as 225,361,295 MiniMed shares, with a maximum exchange ratio of 4.5939 MiniMed shares for every Medtronic share tendered. According to a Barron's report, the swap has become less appealing because MiniMed stock weakened following the announcement. The transaction is designed to shed businesses that offer fewer synergies with the rest of the medical device portfolio, freeing up resources for research and launches in higher-margin segments. Based on current market pricing, the group carries a market capitalization of roughly EUR 97.94 billion.

Four Clearances Land in the Cardiovascular Division

While the spinoff moves toward its conclusion, Medtronic's heart franchise has been collecting regulatory milestones. On Wednesday, the company disclosed that its Affera Prism-2 mapping software won both FDA approval and the European CE mark. European regulators also granted CE certification to the PulseSelect ProxBox adapter, which comes equipped with proximity-indicator software.

The company's clinical pipeline produced further momentum. Medtronic's drug-coated Paclitaxel balloon catheter IN.PACT BTK, aimed at peripheral arterial disease below the knee, received FDA Breakthrough Device designation. A randomized pivotal trial enrolling about 400 patients is in the works.

Reimbursement groundwork is advancing as well. The American Medical Association approved Category I CPT codes for the Altaviva tibial neuromodulation system and the Symplicity Spyral renal denervation system. These codes replace the previous Category III transitional designations and take effect in January 2028. According to the company, they recognize both the clinical evidence and the growing acceptance of the two therapies among specialists, effectively locking in payment structures in the U.S. healthcare market for years to come.

A Mixed Picture for Investors

For shareholders, the landscape remains layered. Regulatory clearances and backing from industry analysts reinforce confidence in Medtronic's longer-term innovation engine, while the corporate restructuring keeps near-term sentiment cautious. Analyst support has arrived alongside these operational advances, offering fresh tailwinds as the company reshapes its portfolio and expands its electrophysiology footprint.